Utility of FIB-4 thresholds to identify patients with at-risk F2-F3 NASH based on screening data from a 2000 patient biopsy confirmed cohort of resmetirom Phase 3 clinical trial, MAESTRO-NASH

Saved in:
Bibliographic Details
Published in:Journal of hepatology 2022-07, Vol.77, p.S75
Main Authors: Schattenberg, Jörn, Alkhouri, Naim, Taub, Rebecca, Hennan, Jim, Noureddin, Mazen, Harrison, Stephen
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0168-8278
DOI:10.1016/S0168-8278(22)00547-5